Board of directors

Dr. Wenche Rolfsen

Chairman of the board

Born: 1952.

Position: Board member and chairman of the board of directors of InDex Pharmaceuticals Holding AB since 2016 and in InDex Pharmaceuticals AB and member of the board of InDex Diagnostics AB since 2011.

Other current assignments: Rolfsen is chairman of the board of BioArctic AB, as well as board member of Swedish Match AB, Recipharm AB and Rolfsen Consulting AB (as of which she also is CEO). Rolfsen is partner in Serendipity Partners.

Prior assignments (last five years): Rolfsen was chairman of Sarsia Seed AS until 2018 and Denator AB until 2014. In addition, she was a board member of Moberg Pharma AB until 2017, Industrifonden until 2016, TFS Trial Form Support International AB until 2015 and Pharmacy Production & Laboratories AB until 2015. Furthermore, she was Acting CEO in InDex during a short period in 2015.

Other relevant experience: Rolfsen has 16 years’ experience in leading positions within pre-clinical research and development at Pharmacia AB. She has been responsible for the early clinical organization at Quintiles Europe and CEO of Quintiles Scandinavia for a total of 11 years. Moreover, she has been a board member of several listed companies since 2005 as well as involved in three previous listings in Sweden and Norway. She holds a PhD in Pharmacology from Uppsala University where she also was associate professor during 9 years.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Indirect holding of 81 224 shares through Rolfsen Consulting AB and direct holding of 400 000 warrants 2016-2019.

Prof. Uli Hacksell

Board member

Born: 1950.

Position: Board member of InDex Pharmaceuticals Holding AB since 2016.

Other current assignments: Hacksell is chairman of the board of Cerecor and Adhera Therapeutics, CEO and board member of Medivir AB, as well as board member of Beactica AB and Uppsala University.

Prior assignments (last five years): Hacksell has been chairman of the board of Glionova AB until 2017, SynActPharma A/S until 2015 and CEO of ACADIA Pharmaceuticals, Inc. until 2015. Hacksell was board member of InDex Pharmaceuticals AB between 2015-2017.

Other relevant experience: Hacksell has over 20 years of international R&D management experience from both large pharmaceutical and biotech companies as well as over 10 years of experience as public company CEO. Hacksell was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from being a private start-up to becoming a public multibillion dollar company. He has previously held various senior executive positions at Astra AB and has held the position of professor in organic chemistry at Uppsala University. He has a PhD from Uppsala University.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Direct holding of 15 000 shares and direct holding of 175 000 warrants 2016-2019.

Dr. Lennart Hansson

Board member

Born: 1956.

Position: Board member of InDexPharmaceuticals Holding AB since 2016.

Other current assignments: Hansson is chairman of the board of Ignitus AB and Sixera Pharma AB as well as board member of Medivir AB, Calliditas Therapeutics AB, Athera Biotechnologies AB, and Cinclus Pharma AG.

Prior assignments (last five years): Hansson was board member of Athera biotechnologies AB until 2018, Malmö Industrifinans AB until 2015 and Uminova Invest AB until 2015. Ha was also deputy board member of Airsonett Holding AB until 2015. Hansson was board member of InDex Pharmaceuticals AB between 2011-2017.

Other relevant experience: Hansson has been engaged in the Life Science unit at Industrifonden since 2008. Previously he has more than 20 years’ experience from pharma and biotech industry in executive position at KabiGen, Symbicom AB, AstraZeneca AB and BioVitrum AB and as CEO for Arexis AB. Between 2006 and 2008 he worked for Karolinska Development AB. He has a PhD from Umeå University.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: No. Hansson is previously employed by Industrifonden.

Shareholding in InDex: Indirect holding of 30 000 shares through Ignitus AB.

Stig Lökke Pedersen

Board member

Born: 1961.

Position: Board member of InDex Pharmaceuticals Holding AB since 2016.

Other current assignments: Pedersen is chairman of the board of Nuevolution AB, Modus Therapeutics AB, moksha8 Ltd, Transmedica A/S and SSI-Diagnostics A/S as well as board member of Union Therapeutics A/S, MSI Ltd, SkyBrands A/S and BroenLab A/S.

Prior assignments (last five years): Pedersen has been chairman of the board of x3 Capital, Microlytic ApS and Ergolet A/S until 2015 and of Chemometec A/S until 2014 as well as board member of Executive Capital A/S until 2014. Pedersen was board member of InDex Pharmaceuticals AB between 2012-2017.

Other relevant experience: Pedersen was during a period of nearly 20 years part of the management team of the Danish pharmaceutical group H. Lundbeck A/S, including 10 years as executive VP and member of Lundbeck’s group management. From 2005 to 2011, Pedersen was also Chief Commercial Officer and responsible for Lundbeck’s global sales and marketing activities. The years prior to Lundbeck he worked for Ciba-Geigy AG (now Novartis) during a number of years in Denmark, Switzerland and South Africa. Pedersen has altogehter worked for more than 30 years in the pharmaceutical industry and also has extensive experience from listed companies as Chairman for 5 years in the Life Science company Chemometec A/S .He holds a Master’s degree in economics from the University of Aalborg.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Indirect holding of 23 809 shares through H&L Invest ApS and direct holding of 175 000 warrants 2016-2019.

Andreas Pennervall

Board member

Born: 1974.

Position: Board member of InDex Pharmaceuticals Holding AB since 2016.

Other current assignments: Pennervall is board member of TSS Holding AB, Apica AB and Fairpoint Advisory AB.

Prior assignments (last five years): Pennervall was board member of KTH Chalmers Capital AB until 2018, of Fält Communication AB, SciBase Holding AB, SciBase AB and SciBase Intressenter AB until 2017 and of Investa Företagskapital AB until 2015. Pennervall was deputy board member of Clavister AB until 2014. Pennervall was board member of InDex Pharmaceuticals AB until 2017.

Other relevant experience: Pennervall works within SEB Venture Capital as investment manager and has since 2013 been actively working with a number of SEB Venture Capital’s portfolio companies within Life Science. He holds a Bachelor of Science in Business Administration and Economics from Umeå University.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: No. Pennervall is employed by SEB Venture Capital.

Shareholding in InDex: